EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Hydroxychloroquine Controversies: Clinical Trials, Epistemology, and the Democratization of Science

Luc Berlivet, Ilana Löwy

Medical Anthropology Quarterly · 2020-12 · 34 (4) · 525-541

DOI: 10.1111/maq.12622 ↗
AbstractBibliografische Angaben

Abstract

Abstract The claim that anti‐malaria drugs, chloroquine and hydroxychloroquine, can cure COVID‐19 became a focus of fierce political battles that pitted promoters of these pharmaceuticals, Presidents Bolsonaro and Trump among them, against “medical elites.” At the center of these battles are different meanings of effectiveness in medicine, the complex role of randomized clinical trials (RCTs) in proving such effectiveness, the task of medical experts and the state in regulating pharmaceuticals, patients’ activism, and the collective production of medical knowledge. This article follows the trajectory of chloroquine and hydroxychloroquine as anti‐COVID‐19 drugs, focusing on the reception of views of their main scientific promoter, the French infectious disease specialist, Didier Raoult. The surprising career of these drugs, our text proposes, is fundamentally a political event, not in the narrow sense of engaging specific political fractions, but in the much broader sense of the politics of public participation in science.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →